source
- Ono Pharma halts ONO-1110 development for depression and anxiety after five Phase 2 failures, continues pain studiesOno Pharma announced that its endocannabinoid modulator ONO-1110 failed to demonstrate efficacy in five Phase 2 trials, prompting the company to stop development for depression and social anxiety.…
- Australia emerges as a hub for early-stage clinical trials thanks to speed, clear regulations and tax incentivesA recent episode of BioSpace’s Denatured podcast featured Jerome Barley of Avion Medical and Ryan Klein of Resolian discussing Australia’s growing appeal for early-stage clinical development. The…